
Vendor-hosted, multi-tenant cloud application that automates Continued Process Verification (CPV) and generates Annual Product Quality Review (APQR) reports from MES, LIMS, ERP, and SAP data. APQR is delivered as a built-in workflow within ValGenesis iCPV, part of the Smart GxP Process Lifecycle Suite.
ValGenesis does not sell a standalone product named "ValGenesis APQR." APQR functionality is delivered as a built-in workflow within ValGenesis iCPV (Continued Process Verification), an application inside the ValGenesis Smart GxP Process Lifecycle Suite. Marketing copy consistently positions iCPV as supporting "digital APQR" and "automated APQR report preparation." Earlier vendor materials reference the same module under two prior names — ValGenesis Process Insight and the iSEE Platform (inherited from the 2022 acquisition of 4tune Engineering / 4TE).
The product is CPV-first, with APQR delivered as a packaged report. It addresses Stage 3 of the FDA's 2011 Process Validation lifecycle. APQR is not a separately licensed module — it is an output type: a configurable, automated report that consolidates evidence of process performance, deviations, corrective actions, and other information required for regulatory compliance.
iCPV/APQR can be deployed standalone but is most often sold to existing ValGenesis VLMS customers as a Stage 3 extension to their Stage 2 validation program. The product is sold as part of the Process Lifecycle Suite alongside iCMC (Chemistry, Manufacturing & Controls / QbD).
Primary stakeholders are MSAT/process validation engineers, QA, and manufacturing science teams. APQR is produced as a by-product of a live, statistically governed CPV programme rather than as an annual data-collection exercise.
The entire ValGenesis Smart GxP platform is purpose-built for FDA/EMA-regulated life sciences (pharma, biopharma, vaccines, cell & gene therapy, CDMO, medical device). There is no horizontal or non-pharma edition.
SaaS, vendor-hosted, in what ValGenesis historically called a "validated private cloud" and now describes as "cloud-native architecture" with encryption, audit trails, and role-based access controls. Underlying public-cloud provider is not declared on the iCPV product page or compliance page; third-party material characterizes VLMS as Azure-hosted but this is unverified by primary sources. Regions and single-tenant options not publicly itemised.
Access is browser-based (HTML5 demos run in modern Chromium/Safari). Mobile execution referenced for the broader VLMS validation execution use case; dedicated mobile apps for APQR sign-off not identified. SSO via SAML/OIDC against AzureAD/Okta referenced indirectly via enterprise customer integration patterns. iCPV positioned as "integrated with LIMS, MES, SAP, and manufacturing systems." Named pre-built connectors are not publicly listed — integration is sold as part of implementation engagement. REST is referenced in third-party stack characterisations; GraphQL/webhook posture unknown. Data residency not publicly specified per region. ISA-88 / ISA-95 alignment for shop-floor data ingest not publicly claimed. No iCPV-specific QPS / dataset-size / batch-throughput benchmarks published.
Pricing is not publicly disclosed: no price list is published, and no per-user, per-tenant, per-site, or per-product metering structure is stated. ValGenesis sells as subscription SaaS through an enterprise direct-sales motion.
A "Book a Demo" call-to-action runs throughout valgenesis.com; no public free trial is offered. Reported deal sizes by segment are undisclosed, as are minimum commitments, setup fees, and validation-support fees. Public references indicate enterprise-class engagements: a 15-year multi-site programme with Bayer, a GSK iCMC deployment, and active customers including Roche, CSL Behring, Boehringer Ingelheim, and Otsuka.
Timeline not vendor-published in numeric form for iCPV. The Teuto case study describes a Brazilian-pharma deployment where the CPV team was reduced from 16 to 5 FTE. A GSK customer testimonial states a six-month roll-out target for iCMC was met — indicative of typical six-month process-suite deployment timelines. Top-20 pharma global rollouts (Bayer 26+ sites) are multi-year programs.
ValGenesis provides implementation through its "Delivery" organization, training through "ValGenesis University," and runs an annual customer conference, ValConnect. Implementation, validation support, and training are paid services on top of subscription. Excel/CSV import supported per typical case-study patterns; iCPV is most often a greenfield CPV deployment replacing paper/Excel rather than a migration off another product. Change management and stakeholder buy-in are the most commonly cited friction points. Data-integration scoping affects realised value, since iCPV's value is gated by the quality of LIMS/MES/ERP integration. Smaller biotechs face proportionately heavier configuration effort.
PharmaSpotter assessment from published vendor and third-party sources. No user reviews are on file for this product.
Users report that paperless operation eliminates handwriting and transcription disputes, accelerates document cycle times by 40–75%, and produces durable audit outcomes (multi-year audit-finding-free streaks). For iCPV specifically, the Teuto reference reports APQR-aligned report cycle time falling from two weeks to three days, and the CPV team reduced from 16 FTE to 5. "Implementing ValGenesis iCPV has transformed our approach to CPV. The integration of our data systems and the comprehensive training from the ValGenesis team have empowered our users, ensuring we meet regulatory standards while enhancing efficiency and data integrity." (Patricia Watanabe, Validation Supervisor, Teuto)
Public product-review evidence specific to iCPV/Process Insight is thin. Teuto is the headline reference, and most testimonial logos on the iCPV product page (GSK, Corden Pharma) lack quantified outcome metrics. The 80% document-generation-acceleration claim for VAL and the projected "50% gain on top of the 40% already realized" are vendor-reported and have not been independently benchmarked by an analyst firm. GAMP 5 self-classification, GxP data-export format, cloud provider, ISO 27001 status, named pre-built connectors, and pricing are not publicly published. Reviewers of the broader platform note training and configuration burden for small organisations. Brand churn (iSEE Platform → Process Insight → iCPV in roughly three years) creates documentation continuity issues.
Share your experience with ValGenesis APQR (iCPV) anonymously. Your insights help pharmaceutical professionals make better software decisions.
Contribute Anonymous FeedbackPublicly disclosed pharmaceutical and biotech organizations
Jump to section